This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Psoraxine

Astralis, Ltd.

Drug Names(s): Psoraxine

Description: Psoraxine, administered by intramuscular injection, is a protein-based therapy that is believed to stimulate cells from the patient's immune system to reverse the inflammatory process responsible for psoriasis symptoms.

Jose O'Daly MD, PhD, Chairman of the Board and ChiefExecutive of Astralis, is a Venezuelan parasitologist. While developing animproved vaccine for leishmaniasis, a parasitic infection transmitted bysandflies and endemic in much of South America, he noticed that vaccinatedpatients affected by psoriasis saw their symptoms resolve. The version ofPsoraxine(R) used in the clinical studies in Venezuela was based on a cellularextract from several species of the Leishmania parasite.

Deal Structure: In 2001 SkyePharma PLC and Astralis announced several agreements concerning the formulation and development Psoraxine. Under the terms of a technology access agreement, SkyePharma will receive from Astralis a US$5 million license fee, for access to DepoFoam and other relevant drug delivery technologies. In addition, through a service agreement, SkyePharma willprovide all development, manufacturing, pre-clinical and clinical development services for second generation Psoraxine, up to the completion of Phase II clinical studies. On completion of Phase II studies, Astralis will offer SkyePharma the option to acquire the worldwide licensing and distribution rightsto Psoraxine. If SkyePharma does not take the option, Astralis will seek a marketing partner to fund Phase III clinical studies and to provide a sales and marketing infrastructure.

SkyePharma and Vectura
In March 2016, the Boards of Skyepharma and Vectura announced that...See full deal structure in Biomedtracker

Partners: Vectura Group


Psoraxine News

Pink Sheet Trademark Review


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug